| Sep 26 |
Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024
|
| Sep 25 |
Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
|
| Sep 25 |
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
|
| Sep 25 |
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
|
| Sep 25 |
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
|
| Sep 24 |
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
|
| Sep 18 |
Bristol Myers Squibb Zeposia shows long-term efficacy
|
| Sep 18 |
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
|
| Sep 17 |
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
|
| Sep 17 |
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
|
